MedTrace Logo

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

NCT02107378 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-11-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).

Conditions

  • Epithelial Ovarian Carcinoma

Interventions

BIOLOGICAL

DCVAC/OvCa

DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin

DRUG

Standard of Care (Paclitaxel or topotecan or doxorubicin)

Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy

Sponsors & Collaborators

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Ales Horacek · Accord Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Czechia
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107378 on ClinicalTrials.gov